WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
WuXi Biologics (2269.HK) has been included in the S&P Global Sustainability Yearbook 2025, marking its third consecutive year in this prestigious publication. The company ranked in the top 1% of the S&P Global Corporate Sustainability Assessment (CSA) Score for 2024, demonstrating exceptional sustainability performance.
Out of 7,690 companies assessed, only 780 across 62 industries were selected for the Yearbook. The company's commitment to sustainability is further evidenced by its inclusion in the 2023 and 2024 Dow Jones Sustainability Indices and numerous other recognitions, including:
- MSCI AAA Rating and EcoVadis Platinum Medal for two consecutive years
- Sustainalytics industry and regional ESG top-rated company for five consecutive years
- CDP Water Security 'A list' member and 'A-' Climate Change score
- FTSE4Good Index Series constituent
- Hang Seng ESG 50 Index listing
WuXi Biologics (2269.HK) è stata inclusa nel S&P Global Sustainability Yearbook 2025, segnando il suo terzo anno consecutivo in questa prestigiosa pubblicazione. L'azienda si è classificata nel top 1% della S&P Global Corporate Sustainability Assessment (CSA) Score per il 2024, dimostrando un'eccezionale performance in sostenibilità.
Su 7.690 aziende valutate, solo 780 provenienti da 62 settori sono state selezionate per il Yearbook. L'impegno dell'azienda verso la sostenibilità è ulteriormente dimostrato dalla sua inclusione negli Indici di Sostenibilità Dow Jones del 2023 e 2024 e da numerosi altri riconoscimenti, tra cui:
- Valutazione MSCI AAA e Medaglia d'Oro EcoVadis per due anni consecutivi
- Azienda top-rated in ESG a livello industriale e regionale da Sustainalytics per cinque anni consecutivi
- Membro della lista 'A' del CDP Water Security e punteggio 'A-' per il cambiamento climatico
- Costituente della FTSE4Good Index Series
- Inclusione nell'indice Hang Seng ESG 50
WuXi Biologics (2269.HK) ha sido incluida en el S&P Global Sustainability Yearbook 2025, marcando su tercer año consecutivo en esta prestigiosa publicación. La compañía se clasificó en el 1% superior de la S&P Global Corporate Sustainability Assessment (CSA) Score para 2024, demostrando un rendimiento excepcional en sostenibilidad.
De 7,690 empresas evaluadas, solo 780 de 62 industrias fueron seleccionadas para el Yearbook. El compromiso de la empresa con la sostenibilidad se evidencia aún más por su inclusión en los Índices de Sostenibilidad de Dow Jones de 2023 y 2024 y por numerosos otros reconocimientos, incluyendo:
- Calificación MSCI AAA y Medalla de Platino EcoVadis durante dos años consecutivos
- Empresa con mejor calificación en ESG a nivel industrial y regional por Sustainalytics durante cinco años consecutivos
- Miembro de la lista 'A' de CDP Water Security y puntuación 'A-' en Cambio Climático
- Miembro de la serie FTSE4Good Index
- Listado en el índice Hang Seng ESG 50
우시 바이오로직스 (2269.HK)는 S&P 글로벌 지속 가능성 연감 2025에 포함되어, 이 권위 있는 출판물에서 3년 연속으로 선정되었습니다. 이 회사는 2024년 S&P 글로벌 기업 지속 가능성 평가(CSA) 점수에서 상위 1%에 랭크되어, 뛰어난 지속 가능성 성과를 보여주었습니다.
7,690개 기업 중에서 62개 산업에서 단 780개 기업만이 연감에 선정되었습니다. 이 회사의 지속 가능성에 대한 헌신은 2023년 및 2024년 다우 존스 지속 가능성 지수에 포함된 것과 여러 다른 인정으로 더욱 입증됩니다. 포함된 인정 목록은 다음과 같습니다:
- 두 해 연속 MSCI AAA 등급 및 EcoVadis 플래티넘 메달
- 다섯 해 연속 Sustainalytics 산업 및 지역 ESG 최고 평가 기업
- CDP 물 안전성 'A 리스트' 회원 및 'A-' 기후 변화 점수
- FTSE4Good 지수 구성원
- 항셍 ESG 50 지수 상장
WuXi Biologics (2269.HK) a été incluse dans le S&P Global Sustainability Yearbook 2025, marquant sa troisième année consécutive dans cette publication prestigieuse. L'entreprise s'est classée dans le top 1% de l'évaluation de durabilité des entreprises S&P Global (CSA) pour 2024, démontrant une performance exceptionnelle en matière de durabilité.
Parmi 7 690 entreprises évaluées, seules 780 issues de 62 secteurs ont été sélectionnées pour le Yearbook. L'engagement de l'entreprise en faveur de la durabilité est également prouvé par son inclusion dans les Indices de Durabilité Dow Jones de 2023 et 2024 et par de nombreuses autres reconnaissances, notamment :
- Note MSCI AAA et Médaille Platine EcoVadis pendant deux années consécutives
- Entreprise la mieux notée en ESG au niveau sectoriel et régional par Sustainalytics pendant cinq années consécutives
- Membre de la liste 'A' de la CDP Water Security et note 'A-' pour le changement climatique
- Membre de la série FTSE4Good Index
- Inscription dans l'indice Hang Seng ESG 50
WuXi Biologics (2269.HK) wurde im S&P Global Sustainability Yearbook 2025 aufgenommen, was das dritte aufeinanderfolgende Jahr in dieser prestigeträchtigen Publikation markiert. Das Unternehmen belegte im S&P Global Corporate Sustainability Assessment (CSA) Score für 2024 die Top 1%, was eine außergewöhnliche Nachhaltigkeitsleistung demonstriert.
Von 7.690 bewerteten Unternehmen wurden nur 780 aus 62 Branchen für das Jahrbuch ausgewählt. Das Engagement des Unternehmens für Nachhaltigkeit wird zusätzlich durch seine Aufnahme in die Dow Jones Sustainability Indices der Jahre 2023 und 2024 sowie durch zahlreiche andere Auszeichnungen belegt, darunter:
- MSCI AAA Bewertung und EcoVadis Platinmedaille für zwei aufeinanderfolgende Jahre
- Fünf Jahre in Folge als branchen- und regionalbestes Unternehmen von Sustainalytics bewertet
- Mitglied der 'A-Liste' der CDP Water Security und 'A-' Klimawandel Punktzahl
- Mitglied der FTSE4Good Index Series
- Auflistung im Hang Seng ESG 50 Index
- None.
- None.
- Ranking in top
1% of S&P Global CSA Score - Inclusion in Global Yearbook for third consecutive year
- Leader in Green CRDMO to drive innovation for a healthier future
The Yearbook aims to distinguish individual companies — within a range of industries — that have demonstrated strong corporate sustainability, based on their S&P Global 2024 CSA Score. Out of the 7,690 companies assessed in the 2024 CSA, only 780 companies, across 62 industries, were recognized as the top performers and selected for inclusion in Yearbook 2025.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are very pleased to be once again selected for inclusion in the Yearbook, a reflection of our steadfast dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide to fulfill ESG commitments, and jointly work with all stakeholders to promote responsible practices throughout the entire value chain."
In the past couple of years, WuXi Biologics has also been named to the 2023 and 2024 Dow Jones Sustainability Indices (DJSI) for its unremitting efforts and notable achievements in promoting sustainable development. In addition, as a participant of United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively contributes to advocating sustainability, and has earned widespread recognition for its efforts. It was granted an MSCI AAA Rating and EcoVadis Platinum Medal for two consecutive years; included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-included-in-sp-global-sustainability-yearbook-2025-302397781.html
SOURCE WuXi Biologics
FAQ
What sustainability achievement did WuXi Biologics (WXXWY) receive in 2025?
How many companies were selected for the S&P Global Sustainability Yearbook 2025?
What major ESG ratings and recognitions has WXXWY received recently?
How has WuXi Biologics (WXXWY) performed in the Dow Jones Sustainability Indices?
What international sustainability initiatives is WXXWY participating in?
